Company news
Simulations Plus, Inc. (NASDAQ:SLP) news
Every Simulations Plus, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch
September 17, 2026
Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris
August 13, 2026
Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results
July 9, 2026
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
July 6, 2026
Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit
June 23, 2026
Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP
June 18, 2026
Simulations Plus to Be Acquired by Altaris For Approximately $375 Million
June 16, 2026
Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference
May 21, 2026
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows
May 6, 2026
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
April 21, 2026
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
April 20, 2026
Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results
April 9, 2026
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
March 26, 2026
Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling
March 26, 2026
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
March 3, 2026
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
February 9, 2026
Simulations Plus to Participate in Upcoming Investor Conferences
February 3, 2026
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
January 21, 2026
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
January 8, 2026
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
December 18, 2025
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
December 17, 2025
Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
December 9, 2025
Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results
December 1, 2025
Simulations Plus Announces Preliminary Fiscal Year 2025 Results and Fiscal Year 2026 Guidance
October 22, 2025
Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design
July 29, 2025
Simulations Plus Invests in Clinical Development Technology Company Nurocor
July 14, 2025
Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
July 14, 2025
Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call
June 18, 2025
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
June 12, 2025
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
June 11, 2025
Simulations Plus Releases ADMET Predictor® 13
June 5, 2025
Simulations Plus Releases DILIsym® 11
May 15, 2025
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
April 21, 2025
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
April 3, 2025
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
March 20, 2025
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
March 10, 2025
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
January 22, 2025
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
January 13, 2025
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
January 7, 2025
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
December 17, 2024
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
November 13, 2024
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
October 30, 2024
Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results
October 23, 2024
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
October 9, 2024
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
October 8, 2024
Simulations Plus Releases DILIsym® X
August 1, 2024
Simulations Plus Releases ADMET Predictor® Version 12
July 30, 2024
Simulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety
July 11, 2024
Simulations Plus Reports Third Quarter Fiscal 2024 Financial Results
July 2, 2024
Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
June 18, 2024